INVOLVEMENT OF CYP2E1 AS A LOW-AFFINITY ENZYME IN PHENACETIN O-DEETHYLATION IN HUMAN LIVER MICROSOMES
|
|
- Antony Johnston
- 5 years ago
- Views:
Transcription
1 /99/ $02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 27, No. 8 Copyright 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. INVOLVEMENT OF CYP2E1 AS A LOW-AFFINITY ENZYME IN PHENACETIN O-DEETHYLATION IN HUMAN LIVER MICROSOMES KAORU KOBAYASHI, MIKI NAKAJIMA, KANAKO OSHIMA, NORIAKI SHIMADA, TSUYOSHI YOKOI, AND KAN CHIBA Laboratory of Biochemical Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, Chiba University, Chiba (K.K., K.O., K.C.); Division of Drug Metabolism, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa (M.N., T.Y.); and Materials Technology Research Laboratories, Daiichi Pure Chemicals Co. Ltd., Ibaraki (N.S.), Japan (Received February 8, 1999; accepted May 3, 1999) This paper is available online at ABSTRACT: Phenacetin O-deethylation (POD) exhibits biphasic kinetics in human liver microsomes. Although cytochrome P-450 (CYP) 1A2 is responsible for the high-affinity component of POD, the enzyme(s) that catalyzes the low-affinity reaction is still unknown. We examined the roles of human CYPs in POD by using human liver microsomes and recombinant CYPs from baculovirus-infected insect cells. Of the recombinant CYPs studied, CYP1A2 showed the highest POD activity. CYP1A1, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 also showed POD activity at 500 M phenacetin. K M values of recombinant CYP1A2 and CYP2E1 (28 2 M and M, respectively) were similar to those of the high- and low-affinity components of POD in pooled human liver microsomes (15 5 and M, respectively). Fluvoxamine (10 M) and anti- Cytochrome P-450 (CYP) 1 consists of a superfamily of hemecontaining monooxygenases (Nelson et al., 1996) that play important roles in the biotransformation of numerous endogenous compounds and xenobiotics, including steroids, fatty acids, drugs, and carcinogens. CYP isoforms exhibit distinct but frequently overlapping substrate specificities (Rendic and Di Carlo, 1997). Fifteen or more different CYP isoforms involved in xenobiotic compound metabolism have been characterized in humans (Parkinson, 1996). The identification of human CYP isoforms responsible for the metabolism of therapeutic agents may predict or explain clinical or toxicological observations, such as drug-drug interactions. Therefore, we use an in vitro approach to characterize the substrate specificity of several CYP isoforms expressed in human liver microsomes. CYP1A2 is one of two enzymes in the CYP1A subfamily (Nelson et al., 1996). In the human liver, CYP1A2 constitutes approximately 13% of total CYP protein (Shimada et al., 1994) and catalyzes the metabolism of a large variety of drugs and carcinogens (Rendic and Di Carlo, 1997). There is wide inter- and intraindividual variation in CYP1A2 activity, and it is known that cigarette smoking causes CYP1A2 antibodies potently inhibited POD activity at 500 M phenacetin in pooled human liver microsomes to 22.8 and 34.2% of controls, respectively. CYP2E1 inhibitors diethyldithiocarbamate and aniline also reduced POD activity. The combination of fluvoxamine (10 M) and aniline (1 mm) further inhibited the residual POD activity not inhibited by fluvoxamine alone. Microsomal POD activity in 12 human livers in the absence of fluvoxamine was correlated with immunoquantified CYP1A2 levels (r 0.961, p <.001) and, in the presence of 10 M fluvoxamine, was correlated with immunoquantified CYP2E1 levels (r 0.589, p <.01) or chlorzoxazone 6-hydroxylase activity (r 0.823, p <.001). These results suggest that CYP2E1 is responsible for the low-affinity component of POD in human liver microsomes. marked induction of the enzyme (Sesardic et al., 1988; Nakajima et al., 1994). Phenacetin undergoes oxidative O-deethylation to yield acetaminophen by CYP1A2 and has therefore been used to assess the catalytic activity of CYP1A2 in vivo and in vitro or to investigate its regulation (Butler et al., 1989; Xiaodong et al., 1994; Bartoli et al., 1996). However, several studies have reported that the kinetics of phenacetin O-deethylation (POD) in human liver microsomes is biphasic (Boobis et al., 1981; Kahn et al., 1985; Gillam and Reilly, 1988; Tassaneeyakul et al., 1993), which could indicate the involvement of more than one isoform of CYP. The high-affinity component of POD is well established as a marker reaction for CYP1A2 function in human liver microsomes. However, it is unclear which enzyme(s) catalyzes the low-affinity reaction. Thus, we examined the roles of several human CYPs, as well as CYP1A2, in POD by using human liver microsomes and microsomes from baculovirus-infected insect cells expressing individual human CYPs. Materials and Methods Chemicals. Fluvoxamine maleate was a gift from Solvay Meiji (Tokyo, Japan). Sulfaphenazole and S-mephenytoin were purchased from Daiichi Pure Chemicals (Tokyo, Japan). Troleandomycin (TAO) was purchased from Sigma 1 Abbreviations used are: CYP, cytochrome P-450; POD, phenacetin O-deethylation; TAO, troleandomycin; DDC, N,N- diethyldithiocarbamate. (St. Louis, MO). NADP, glucose 6-phosphate, and glucose 6-phosphate dehydrogenase were purchased from Oriental Yeast (Tokyo, Japan). HPLCgrade acetonitrile and methanol, and analytical grade phenacetin, paracetamol Send reprint requests to: Kaoru Kobayashi, Ph.D., Laboratory of Biochemical Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, (acetaminophen), aniline hydrochloride, caffeine, quinidine sodium, N,N-diethyldithiocarbamate (DDC) trihydrate, and other reagents were purchased Chiba University, Yayoi-cho 1-33, Inage-ku, Chiba , Japan. kaoruk@p.chiba-u.ac.jp from Wako Pure Chemical Industries (Osaka, Japan). Anti-rat CYP1A1, CYP1A2, CYP2C, CYP2D6, and CYP3A rabbit sera and monoclonal anti- 860
2 INVOLVEMENT OF CYP2E1 IN PHENACETIN O-DEETHYLATION 861 bodies against human CYP2A6 or CYP2E1 were obtained from Daiichi Pure Chemicals. Enzyme Preparations. Pooled human liver microsomes (lot 2) consisted of a mixture of microsomes prepared from six individual donors, and individual microsomes from 12 human liver specimens (HG3, HG6, HG23, HG30, HG42, HG43, HG56, HG66, HG70, HG89, HG93, and HG112) were obtained from Gentest (Woburn, MA). Immunochemically determined CYP contents and isoform specific activities of each CYP isoform in the microsomes were provided by the manufacturer as follows. Levels of CYP1A2, CYP2A6, CYP2B6, CYP2D6, CYP2E1, and CYP3A4 were determined by immunoblot analysis. Specific activities of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A were determined by the activities against phenacetin O-deethylase (200 M), coumarin 7-hydroxylase (200 M), S-mephenytoin N-demethylase (100 M), diclofenac 4 -hydroxylase (100 M), S-mephenytoin 4 -hydroxylase (100 M), bufuralol 1 -hydroxylase (25 M), chlorzoxazone 6-hydroxylase (100 M), and testosterone 6 -hydroxylase (200 M), respectively. Microsomes prepared from baculovirus-infected insect cells expressing CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP3A4 b 5 (CYP3A4 coexpressed with cytochrome b 5 ), CYP3A4 (CYP3A4 without b 5 ), CYP3A5, and CYP4A11 were obtained from Gentest. All recombinant CYPs were coexpressed with NADPH CYP oxidoreductase. POD Assay. Microsomal POD activity was determined by measuring the rate of acetaminophen formation at 37 C as described previously (Kobayashi et al., 1998). Briefly, a typical incubation mixture consisted of 0.1 mg/ml human liver microsomal protein or a 20 pmol/ml CYP concentration from baculovirus-infected insect cells, 0.1 M potassium phosphate buffer (ph 7.4), 0.1 mm EDTA, an NADPH-generating system (0.5 mm NADP, 2.0 mm glucose 6-phosphate, 1 IU/ml glucose 6-phosphate dehydrogenase, 4 mm MgCl 2 ), and phenacetin in a final volume of 250 l. Phenacetin dissolved in methanol was added to test tubes and evaporated with a vacuum evaporator at 40 C. The incubation mixture, except for microsomes and the NADPHgenerating system, were redissolved by sonication. The mixture including microsomes and the NADPH-generating system was incubated at 37 C for 30 min. After the reaction was stopped by adding 100 l of cold acetonitrile, 50 l of caffeine (5 g/ml in methanol) was added as an internal standard. The mixture was centrifuged at 10,000g for 5 min, and the supernatant was evaporated by a vacuum evaporator at 40 C for 15 min. Fifty microliters of the remaining sample was analyzed by HPLC. HPLC analysis was performed with an L-6000 pump (Hitachi, Tokyo, Japan), an L-4000 UV detector (Hitachi), an AS-2000 autosampler (Hitachi), a D-2500 integrator (Hitachi), and a CAPCELL PAK C 18 UG120 column (4.6 mm 250 mm, 5 m; Shiseido, Tokyo, Japan). The mobile phase consisted of 50 mm potassium dihydrogen phosphate and acetonitrile at a ratio of 85:15, v/v (%), delivered at a flow rate of 0.7 ml/min. The eluate was monitored at a wavelength of 245 nm. The column temperature was maintained at 30 C. Acetaminophen was quantified by comparison with standard curves by using the peak-height ratio method. Kinetic Analyses. Kinetic studies were performed with pooled human liver microsomes and recombinant CYPs from baculovirus-infected insect cells (CYP1A1, CYP1A2, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 b 5 ). POD activities were determined with phenacetin concentrations ranging from 1 M to 1 mm. All reactions were performed within a linear range with respect to protein concentration and incubation time. Briefly, 0.1 mg/ml human liver microsomes, 8 pmol/ml recombinant CYP1A1 or CYP1A2, 20 pmol/ml recombinant CYP2C19, CYP2D6, or CYP2E1, and 40 pmol/ml recombinant CYP3A4 b 5 were incubated for 30 min. Michaelis-Menten kinetic parameters for POD in human liver microsomes were estimated by fitting the data to the following equation: V V max1 S/ K M1 S V max2 S/ K M2 S (1) where V is the velocity of POD, S is the concentration of phenacetin in the incubation mixture, K M1 and K M2 are the affinity constants for the high- and low-affinity components, respectively, and V max1 and V max2 are the maximum enzyme velocities for the high- and low-affinity components, respectively. Kinetic parameters were estimated initially by graphical analysis of Eadie- Hofstee plots, and the values were subsequently used as initial estimates for the MULTI nonlinear least-squares regression analysis (Yamaoka et al., 1981). When reactions followed a simple Michaelis-Menten kinetic behavior (i.e., a one-enzyme kinetic approach), the kinetic parameters (K M, V max, and V max / K M ) of recombinant CYPs were estimated by nonlinear least-squares regression analysis. Inhibition Study. CYP isoform-specific inhibitors or substrates (i.e., compounds able to act as competitive inhibitors) were used to study POD activity with 500 M phenacetin in pooled human liver microsomes. Isoform-specific inhibitors and alternative substrates used were 0.1 to 100 M fluvoxamine (CYP1A; Pastrakuljic et al., 1997), 1 to 100 M sulfaphenazole (CYP2C9; Newton et al., 1995), 1 to 100 M S-mephenytoin (CYP2C19; Küpfer and Preisig, 1984), 1 to 100 M quinidine (CYP2D6; Guengerich et al., 1986), 1 to 1000 M DDC (CYP2E1; Newton et al., 1995), 1 to 1000 M aniline (CYP2E1; Morgan et al., 1982), and 1 to 100 M TAO (CYP3A; Newton et al., 1995). Incubations were carried out as mentioned above except for TAO and DDC, which were preincubated in the presence of the NADPH-generating system at 37 C for 15 min, and the reaction was initiated by the addition of substrate dissolved in water. The immunoinhibition of POD activity was examined by preincubating human liver microsomal samples (25 g of microsomal protein) with various amounts of antibodies for 1honice. Phenacetin (500 M) and other components of the incubation medium were then added, and the reaction was carried out as described above. The amounts of anti-rat CYP1A1, CYP1A2, CYP2C, CYP2D6, or CYP3A rabbit sera and monoclonal antibodies against human CYP2A6 or CYP2E1 used were up to 200 and 100 l/mg microsomal protein, respectively. These amounts were verified to inhibit the specific activities of corresponding CYP isoforms in human liver microsomes (Daiichi Pure Chemicals, unpublished data). Correlation Study. Correlations between the POD activities at a 500 M substrate concentration in the absence or presence of 10 M fluvoxamine and the catalytic activity of phenacetin O-deethylase (CYP1A2), coumarin 7-hydroxylase (CYP2A6), S-mephenytoin N-demethylase (CYP2B6), diclofenac 4 -hydroxylase (CYP2C9), S-mephenytoin 4 -hydroxylase (CYP2C19), bufuralol 1 -hydroxylase (CYP2D6), chlorzoxazone 6-hydroxylase (CYP2E1), and testosterone 6 -hydroxylase (CYP3A) were studied by using microsomes from 12 human livers. Similarly, POD activity at a 500 M substrate concentration in the absence or presence of 10 M fluvoxamine in microsomes from 12 human livers was compared with immunoquantified levels of CYP1A2, CYP2A6, CYP2B6, CYP2D6, CYP2E1, and CYP3A4. For correlation analysis, the isoform specific activities and immunochemically determined CYP levels for each microsomal CYP isoform were provided by the manufacturer. Statistical Analysis. Statistical significance was determined with the Student s t test for unpaired samples, with p.05 considered statistically significant. Data represent the mean of duplicate or triplicate measurements for every experiment. Correlation coefficients (r) were determined by Pearson s product-moment method. Results Kinetics of POD in Pooled Human Liver Microsomes. The Eadie-Hofstee plot for POD in pooled human liver microsomes in the present study was biphasic (data not shown), as reported previously (Boobis et al., 1981; Kahn et al., 1985; Gillam and Reilly, 1988; Tassaneeyakul et al., 1993). Apparent K M values for the high- and low-affinity components were 15 5 and M, respectively. The V max values for the high- and low-affinity components were and pmol/min/mg of protein, respectively. Activity and Kinetics of POD in Recombinant CYPs. POD activity at 500 M substrate in microsomes from baculovirus-infected insect cells expressing individual human CYPs was determined (Fig. 1). Of the recombinant CYPs studied, CYP1A2 showed the highest activities (42.1 pmol/min/pmol of CYP). CYP1A1, CYP2C19, CYP2D6, and CYP2E1 showed POD activities of 22.0, 15.1, 5.4, and 2.9 pmol/min/pmol of CYP, respectively. CYP3A4 b 5 showed higher POD activity than did CYP3A4 (5.2 versus 1.2 pmol/min/pmol
3 862 KOBAYASHI ET AL. TABLE 1 Michaelis-Menten kinetic parameters of POD in microsomes from baculovirusinfected insect cells expressing CYP1A1, CYP1A2, or CYP2E1 CYP a K m V max M pmol/min/pmol CYP CYP1A CYP1A CYP2E a Eight pmol/ml CYP1A1 or CYP1A2 and 20 pmol/ml CYP2E1 were incubated for 30 min, respectively. The concentration range of phenacetin used was 1 M to1mm. FIG. 1.POD activity in microsomes from baculovirus-infected insect cells expressing individual human CYPs. Substrate (500 M phenacetin) was incubated at 37 C for 30 min with microsomes (20 pmol of CYP/ml) from baculovirus-infected insect cells expressing CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A4 b 5, CYP3A5, and CYP4A11. Each column represents the mean of duplicate experiments. of CYP). Negligible POD activity ( 10 pmol of product) was detected in control microsomes and microsomes expressing CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP3A5, and CYP4A11. Kinetic analyses were performed with microsomes from baculovirus-infected insect cells expressing CYP1A1, CYP1A2, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 b 5. POD activity of recombinant CYP1A1, CYP1A2, and CYP2E1 exhibited typical Michaelis-Menten kinetics, and kinetic parameters were estimated for CYP1A1, CYP1A2, and CYP2E1 as described above. As shown in Table 1, CYP1A2 showed the highest V max values ( pmol/min/pmol of CYP), whereas CYP1A1 and CYP2E1 exhibited approximately 2- and 11-fold lower V max values, respectively. The apparent K M value of CYP2E1 ( M) was approximately 30-fold higher than those of CYP1A1 and CYP1A2 (27 3 and 28 2 M, respectively), indicating its lower affinity for phenacetin. K M values of recombinant CYP2C19, CYP2D6, and CYP3A4 b 5 could not be estimated because plots of V versus S were linear (data not shown). Inhibition Study. CYP isoform-specific xenobiotic compounds were screened for inhibitory effects on POD activity in pooled human liver microsomes (Fig. 2). Fluvoxamine inhibited POD activity in a concentration-dependent manner, with an IC 50 value of 1.8 M. DDC inhibited POD activity by 50% at concentrations above 100 M. POD activity was inhibited to 87 and 73% of control activity by 100 M and 1 mm aniline, respectively. The extent of inhibition by quinidine or sulfaphenazole on POD activity was slight ( 20%), even at concentrations of 100 M. No effects of S-mephenytoin (CYP2C19 substrate) and TAO (CYP3A inhibitor) were observed with inhibitor concentrations up to 100 M. Similar results were obtained in antibody inhibition studies. As shown in Fig. 3, anti-cyp1a2 serum inhibited POD activity to 34.2% of control activity at 40 l/mg microsomal protein. No effects were observed with antibodies against CYP1A1, CYP2C, CYP2D6, CYP3A, CYP2A6, or CYP2E1. Effects of Fluvoxamine and Aniline on POD Activity. The effects of 10 M fluvoxamine and 1 mm aniline, alone and in combination, on POD activity in pooled human liver microsomes were examined. The concentrations of fluvoxamine and aniline were selected based on the following observations. Fluvoxamine (10 M) inhibited CYP1A2-catalyzed POD activity to 19% of control activity but had little effect on CYP2E1-catalyzed activity. Conversely, 1 mm FIG. 2.Effects of specific inhibitors for CYP isoforms on POD activity in pooled human liver microsomes. The concentration of phenacetin used was 500 M, and the range of inhibitor concentrations was 0.1 to 100 or 1000 M. Each data point represents the mean of duplicate experiments. aniline completely inhibited CYP2E1-catalyzed POD activity but had little effect on CYP1A2-catalyzed activity (M. Nakajima, K. Kobayashi, K. Oshima, N. Shimada, S. Tokudome, K. Chiba and T. Yokoi, submitted). As shown in Fig. 4, 10 M fluvoxamine potently inhibited POD activity to % of control (p.005). Aniline (1 mm) also significantly inhibited POD activity to % of control (p.05). The combination of fluvoxamine and aniline inhibited POD activity to % of control (p.005). The inhibition by combined fluvoxamine and aniline was significantly more potent as compared with fluvoxamine (p.005) or aniline (p.01) alone. To clarify the contributions of CYP1A2 and CYP2E1 to POD at 500 M phenacetin in individual microsomes of human livers, the effects of 10 M fluvoxamine alone and in combination with 1 mm aniline on POD activity in microsomes from 12 human livers were determined. Although 10 M fluvoxamine inhibited POD activity in all human liver microsomes, large interindividual differences were observed in the inhibitory effects of fluvoxamine in the 12 human liver microsome preparations (Fig. 5). Residual POD activity ranged from 10.3 (HG30) to 73.9% (HG3) of control activities. The combination of fluvoxamine and aniline potently inhibited POD activity to less than 12% of control activities in all 12 human liver microsome samples. Correlation Study. As shown in Fig. 6, POD activity in the 12 human liver microsome preparations at 500 M phenacetin in the absence of fluvoxamine was significantly correlated with POD activity at 200 M phenacetin (r 0.981, p.001) and also correlated with immunoquantified CYP1A2 levels (r 0.961, p.001). No other significant correlations were observed between POD activity in the absence of fluvoxamine and catalytic activities of coumarin 7-hydroxylase (r 0.145), S-mephenytoin N-demethylase (r 0.092),
4 INVOLVEMENT OF CYP2E1 IN PHENACETIN O-DEETHYLATION 863 FIG. 3.Immunoinhibition of POD activity by antibodies against CYP isoforms in pooled human liver microsomes. Human liver microsomes (25 g of microsomal protein) were preincubated with various amounts of antibodies for 1honicebefore incubation with 500 M phenacetin. Each data point represents the mean of duplicate experiments. diclofenac 4 -hydroxylase (r 0.563), S-mephenytoin 4 -hydroxylase (r 0.333), bufuralol 1 -hydroxylase (r 0.078), chlorzoxazone 6-hydroxylase (r 0.110), or testosterone 6 -hydroxylase (r 0.000). POD activity in the absence of fluvoxamine was also not correlated with the immunoquantified levels of CYP2A6 (r 0.092), CYP2B6 (r 0.285), CYP2D6 (r 0.342), CYP2E1 (r 0.000), or CYP3A4 (r 0.210). In the presence of 10 M fluvoxamine, POD activity at a 500 M substrate concentration was not significantly correlated with POD activity at 200 M phenacetin (r 0.295) and immunoquantified CYP1A2 levels (r 0.282). However, POD activity at a 500 M substrate concentration in the presence of fluvoxamine was significantly correlated with chlorzoxazone 6-hydroxylase activity (r 0.823, p.001) and also with immunoquantified CYP2E1 levels (r 0.589, p.01) as shown in Fig. 7. POD activity in the presence of fluvoxamine was not significantly correlated with catalytic activities of coumarin 7-hydroxylase (r 0.285), S-mephenytoin N- demethylase (r 0.044), diclofenac 4 -hydroxylase (r 0.255), S-mephenytoin 4 -hydroxylase (r 0.110), bufuralol 1 -hydroxylase (r 0.567), or testosterone 6 -hydroxylase (r 0.045) and with immunoquantified levels of CYP2A6 (r 0.141), CYP2B6 (r 0.095), CYP2D6 (r 0.348), or CYP3A4 (r 0.114). FIG. 4.Effects of fluvoxamine and aniline on POD activity in pooled human liver microsomes. The concentration of phenacetin used was 500 M. Each column represents the mean S.D. of three different experiments. Residual activities with 10 M fluvoxamine and 1 mm aniline, alone and in combination, are expressed as percentages of control activity. Control activity was pmol/min/mg. *p.05; ***p.005 compared to control; p.005 compared to 10 M fluvoxamine; p.01 compared to 1 mm aniline. FIG. 5.Effects of fluvoxamine alone and in combination with aniline on POD activity in 12 human liver microsomes. The concentration of phenacetin used was 500 M. The residual activities with 10 M fluvoxamine and in combination with 1 mm aniline were expressed as percentages of control activity. Each column represents the mean of duplicate experiments. Discussion POD is widely used as one of the prototypical reactions catalyzed by CYP1A2 in human liver microsomes. However, several studies have reported that the kinetics of POD in human liver microsomes are biphasic (Boobis et al., 1981; Kahn et al., 1985; Gillam and Reilly, 1988; Tassaneeyakul et al., 1993), suggesting the involvement of more than one CYP isoform. Therefore, we examined the roles of several human CYPs in POD by using 13 recombinant CYP isoforms: CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, and CYP4A11. Figure 1 shows that CYP1A2 exhibited the highest specific activity, followed by CYP1A1 and CYP2C19. CYP2D6, CYP2E1, and CYP3A4 coexpressed with b 5 also interacted with phenacetin, although with low activities. These results suggested that CYP1A2, CYP1A1, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 could catalyze POD in human liver microsomes.
5 864 KOBAYASHI ET AL. FIG. 6.Correlation between POD activity at 500 M phenacetin and that at 200 M phenacetin or immunoquantified levels of CYP1A2 in 12 human liver microsomes. POD activity in 12 human liver microsomes at 500 M phenacetin was compared with POD activity at 200 M phenacetin (A) or immunoquantified levels of CYP1A2 (B). Each data point represents the mean of duplicate experiments. FIG. 7.Correlation between POD activity at 500 M phenacetin in the presence of fluvoxamine and chlorzoxazone 6-hydroxylase activity and immunoquantified levels of CYP2E1 in 12 human liver microsomes. POD activity in 12 human liver microsomes at 500 M phenacetin in the presence of 10 M fluvoxamine was compared to chlorzoxazone 6-hydroxylase activity (A) or immunoquantified levels of CYP2E1 (B). Each data point represents the mean of duplicate experiments. The biphasic liver microsomal POD kinetics observed in the present study are consistent with results of previous human in vitro kinetic studies (Boobis et al., 1981; Kahn et al., 1985; Gillam and Reilly, 1988; Tassaneeyakul et al., 1993). The apparent K M values for the high- and low-affinity components of POD activity in pooled human liver microsomes obtained from this study were of a similar order to those from several previous reports (Boobis et al., 1981; Kahn et al., 1985; Gillam and Reilly, 1988; Tassaneeyakul et al., 1993). To determine the contribution of individual CYP isoforms to the highand low-affinity components of POD in human liver microsomes, the apparent K M values of recombinant CYP isoforms for POD were compared with those of the high- and low-affinity components of POD in human liver microsomes. The K M value of the high-affinity component in pooled human liver microsomes was close to that of recombinant CYP1A2 or CYP1A1 (Table 1). In addition, anti- CYP1A2 antibodies specifically inhibited POD activity at 500 M phenacetin, but anti-cyp1a1 antibodies did not (Fig. 3). Therefore, CYP1A1 was considered not to contribute to POD in human liver microsomes. These observations are in agreement with the proposal (Sesardic et al., 1988) that CYP1A2 is responsible for the highaffinity component of POD in human liver microsomes and for the low expression or lack of expression of CYP1A1 in uninduced human liver (Murray et al., 1993). The K M value of the low-affinity POD component in pooled human liver microsomes was similar to that of recombinant CYP2E1 (Table 1). To our knowledge, this is the first report that CYP2E1 is responsible for POD activity as the low-affinity enzyme in human liver microsomes. Therefore, additional studies, including selective inhibition and correlation analyses, were conducted to evaluate the role of CYP2E1 in POD. The contribution of CYP2E1 to POD was supported by a number of observations. First, CYP2E1 inhibitors, DDC and aniline, reduced POD activity at 500 M phenacetin in pooled human liver microsomes (Fig. 2). Second, the combination of fluvoxamine and aniline further inhibited the residual POD activity not inhibited by fluvoxamine alone in both pooled and individual microsome preparations from human livers (Figs. 4 and 5). Third, POD activity in 12 human liver microsome preparations at 500 M phenacetin in the presence of 10 M fluvoxamine significantly correlated with immunoquantified CYP2E1 levels and chlorzoxazone 6-hydroxylase activity, which is catalyzed by CYP2E1 (Fig. 7). Taken together, these observations suggested that CYP2E1 was responsible for the lowaffinity component of POD in human liver microsomes and was involved in the reaction at high substrate concentrations. Experiments with pooled human liver microsomes revealed that anti-cyp1a2 antibody specifically inhibited POD activity at a substrate concentration of 500 M, but anti-cyp2e1 antibody did not (Fig. 3). In addition, the inhibition of POD activity by 1 mm aniline was weaker than that by 10 M fluvoxamine (Fig. 4). These results suggested that CYP1A2 predominantly catalyzed POD at substrate concentrations of 500 M in pooled human liver microsomes and that CYP2E1 was involved in the reaction as a minor enzyme. However, inhibition experiments performed on microsomes prepared from 12 individual human livers indicated that large differences between individuals were observed in the inhibitory effects of 10 M fluvoxamine (Fig. 5). The residual percentages of POD activity not inhibited by 10 M fluvoxamine ranged from 10.3 (HG30) to 73.9% (HG3) of control activities. Interestingly, the residual percentages of POD activity not inhibited by 10 M fluvoxamine negatively correlated with immunoquantified levels of CYP1A2 (r 0.752, p.01). These results suggested that there were large interindividual differences in the contribution of CYP1A2 to POD at 500 M phenacetin in human liver microsomes, and that these differences were dependent on CYP1A2 levels in individual microsomes of human livers. In addition, the combination of 10 M fluvoxamine and 1 mm aniline potently inhibited POD activity at 500 M phenacetin in all human liver microsome preparations studied. Therefore, the contribution of CYP2E1 to POD at 500 M phenacetin may be significant in human liver microsomes with low CYP1A2 contents. The correlation study with the 12 human liver microsome preparations indicated that POD activity did not correlate with the specific activities and immunoquantified levels of CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, or CYP3A, regardless of the presence or absence of fluvoxamine. In addition, antibodies against CYP2A6, CYP2B6, CYP2C, CYP2D6, and CYP3A did not inhibit POD activity at 500 M phenacetin in pooled human liver microsomes (Fig. 3). In experiments with recombinant CYPs, CYP2A6, CYP2B6, and CYP2C9 failed to catalyze POD (Fig. 1). Although recombinant CYP2C19, CYP2D6, and CYP3A4 exhibited the significant POD activities (Fig. 1), K M values could not be estimated because of linear plots of V versus S. These results suggested that CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 play negligible roles in POD in human liver microsomes.
6 INVOLVEMENT OF CYP2E1 IN PHENACETIN O-DEETHYLATION 865 In conclusion, it appears that CYP1A2 and CYP2E1 are primarily involved in POD in human liver microsomes as high- and low-affinity enzymes, respectively. To our knowledge, this is the first study to present data that CYP2E1 is responsible for POD in human liver microsomes as the low-affinity enzyme. In human liver microsomes with low CYP1A2 contents, CYP2E1 may make a significant contribution to POD. At least in vivo, POD is considered to be mainly catalyzed by CYP1A2, which is a high-affinity enzyme of POD (Xiaodong et al., 1994; Bartoli et al., 1996). However, we should take into account the possibility that CYP2E1 may also contribute to POD activity at high substrate concentrations, when POD is used as a marker reaction for CYP1A2 function in human liver microsomes. References Bartoli A, Xiaodong S, Gatti G, Cipolla G, Marchiselli R and Perucca E (1996) The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: A comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate. Ther Drug Monit 18: Boobis AR, Kahn GC, Whyte C, Brodie MJ and Davies DS (1981) Biphasic O-deethylation of phenacetin and 7-ethoxycoumarin by human and rat liver microsomal fractions. Biochem Pharmacol 30: Butler MA, Iwasaki M, Guengerich FP and Kadlubar FF (1989) Human cytochrome P-450 PA (P450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 86: Gillam EM and Reilly PB (1988) Phenacetin O-deethylation by human liver microsomes: Kinetics and propranolol inhibition. Xenobiotica 18: Guengerich FP, Müller-Enoch D and Blair IA (1986) Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 30: Kahn GC, Boobis AR, Brodie MJ, Toverud EL, Murray S and Davies DS (1985) Phenacetin O-deethylase: An activity of a cytochrome P-450 showing genetic linkage with that catalysing the 4-hydroxylation of debrisoquine? Br J Clin Pharmacol 20: Kobayashi K, Nakajima M, Chiba K, Yamamoto T, Tani M, Ishizaki T and Kuroiwa Y (1998) Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2. Br J Clin Pharmacol 45: Küpfer A and Preisig R (1984) Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26: Morgan ET, Koop DR and Coon MJ (1982) Catalytic activity of cytochrome P-450 isozyme 3a isolated from liver microsomes of ethanol-treated rabbits. Oxidation of alcohols. J Biol Chem 257: Murray BP, Edwards RJ, Murray S, Singleton AM, Davies DS and Boobis AR (1993) Human hepatic CYP1A1 and CYP1A2 content, determined with specific anti-peptide antibodies, correlates with the mutagenic activation of PhIP. Carcinogenesis 14: Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF and Kamataki T (1994) Phenotyping of CYP1A2 in Japanese population analysis of caffeine urinary metabolites: Absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomark Prev 3: Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC and Nebert DW (1996) P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1 42. Newton DJ, Wang RW and Lu AYH (1995) Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23: Parkinson A (1996) An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol Pharmacol 24: Pastrakuljic A, Tang BK, Roberts EA and Kalow W (1997) Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochem Pharmacol 53: Rendic S and Di Carlo FJ (1997) Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29: Sesardic D, Boobis AR, Edwards RJ and Davies DS (1988) A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 26: Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV and Miners JO (1993) Specificity of substrate and inhibitor probes for human cytochrome P450 1A1 and 1A2. J Pharmacol Exp Ther 265: Xiaodong S, Gatti G, Bartoli A, Cipolla G, Crema F and Perucca E (1994) Omeprazole does not enhance the metabolism of phenacetin, a marker of CYP1A2 activity, in healthy volunteers. Ther Drug Monit 16: Yamaoka K, Tanigawara Y, Nakagawa T and Uno T (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobio-Dyn 4:
Arena Pharmaceuticals, Inc., Department of Drug Metabolism and Pharmacokinetics, San Diego, California
1521-009X/12/4004-761 771$25.00 DRUG METABOLISM AND DISPOSITION Vol. 40, No. 4 Copyright 2012 by The American Society for Pharmacology and Experimental Therapeutics 43414/3759637 DMD 40:761 771, 2012 Identification
More informationDifferential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes
Differential selectivity of cytochrome P4 inhibitors against probe substrates in human and rat liver microsomes Victoria A. Eagling, John F. Tjia & David J. Back Department of Pharmacology & Therapeutics,
More informationInvolvement of CYP2C8 and UGT1A9 in the metabolism of a novel gastroprokinetic agent, Z-338
Involvement of CYP2C8 and UGT1A9 in the metabolism of a novel gastroprokinetic agent, Z-338 S. Furuta 1, E. Kamada 1, T. Sugimoto 1, Y. Kawabata 1, X. C. Wu 2, J. Skibbe 3, E. Usuki 3, A. Parkinson 3 and
More informationCYP2A6 AND CYP2B6 ARE INVOLVED IN NORNICOTINE FORMATION FROM NICOTINE IN HUMANS: INTERINDIVIDUAL DIFFERENCES IN THESE CONTRIBUTIONS
0090-9556/05/3312-1811 1818$20.00 DRUG METABOLISM AND DISPOSITION Vol. 33, No. 12 Copyright 2005 by The American Society for Pharmacology and Experimental Therapeutics 6254/3063240 DMD 33:1811 1818, 2005
More informationReceived May 30, 2007; accepted August 15, 2007
0090-9556/07/3511-1990 1995$20.00 DRUG METABOLISM AND DISPOSITION Vol. 35, No. 11 Copyright 2007 by The American Society for Pharmacology and Experimental Therapeutics 16816/3267964 DMD 35:1990 1995, 2007
More informationAND LIVER MICROSOMAL P-450 PROFILES
0090-9556/99/2706-0655 666$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 27, No. 6 Copyright 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. DEVELOPMENT OF
More informationEVALUATION OF CYTOCHROME P450 PROBE SUBSTRATES COMMONLY USED BY THE PHARMACEUTICAL INDUSTRY TO STUDY IN VITRO DRUG INTERACTIONS
0090-9556/02/3012-1311 1319 DRUG METABOLISM AND DISPOSITION Vol. 30, No. 12 U.S. Government work not protected by U.S. copyright 548/1028208 DMD 30:1311 1319, 2002 Printed in U.S.A. EVALUATION OF CYTOCHROME
More informationXTreme 200 Human Liver Microsomes Lot No Human Liver Microsomes Pool of 200 (100 Male and 100 Female) Suspension medium: 250 mm sucrose
XTreme 200 Human Liver Microsomes Lot No. 1710084 Human Liver Microsomes Pool of 200 (100 Male and 100 Female) Suspension medium: 250 mm sucrose H2610 0.5 ml at 20 mg/ml H2620 1.0 ml at 20 mg/ml H2630
More informationCYP2A6 and CYP2B6 are involved in nornicotine formation from nicotine in humans: Interindividual differences in these contributions
DMD Fast This article Forward. has not Published been copyedited on and August formatted. 31, The 2005 final version as doi:10.1124/dmd.105.006254 may differ from this version. CYP2A6 and CYP2B6 are involved
More informationROLE OF CYTOCHROME P-4502C9 IN IRBESARTAN OXIDATION BY HUMAN LIVER MICROSOMES
0090-9556/99/2702-0288 296$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 27, No. 2 Copyright 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. ROLE OF CYTOCHROME
More informationMETABOLISM OF ( )- AND ( )-LIMONENES TO RESPECTIVE CARVEOLS AND PERILLYL ALCOHOLS BY CYP2C9 AND CYP2C19 IN HUMAN LIVER MICROSOMES
0090-9556/02/3005-602 607$7.00 DRUG METABOLISM AND DISPOSITION Vol. 30, No. 5 Copyright 2002 by The American Society for Pharmacology and Experimental Therapeutics 641/981193 DMD 30:602 607, 2002 Printed
More informationLarge interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity
et al. DOI:1.146/j.1365-2125.3.197.x British Journal of Clinical Pharmacology Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity
More informationVALIDATION OF BUPROPION HYDROXYLATION AS A SELECTIVE MARKER OF HUMAN CYTOCHROME P450 2B6 CATALYTIC ACTIVITY
0090-9556/00/2810-1222 1230$03.00/0 DRUG METABOLISM AND DISPOSITION Vol. 28, No. 10 Copyright 2000 by The American Society for Pharmacology and Experimental Therapeutics 163/855917 DMD 28:1222 1230, 2000
More informationIdentification of Cytochrome P450 Isoforms Involved in Citalopram N-Demethylation by Human Liver Microsomes 1
0022-3565/97/2802-0927$03.00/0 THE JOURNAL OF PHARMACOLOGY A EXPERIMENTAL THERAPEUTICS Vol. 280, No. 2 Copyright 1997 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A.
More informationIN VITRO IDENTIFICATION OF THE HUMAN CYTOCHROME P450 ENZYMES INVOLVED IN THE METABOLISM OF R( )- AND S( )-CARVEDILOL
0090-9556/97/2508-0970 977$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 25, No. 8 Copyright 1997 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. IN VITRO IDENTIFICATION
More informationMetabolism and metabolic inhibition of cilnidipine in human liver microsomes 1
263 2003, Acta Pharmacologica Sinica Chinese Pharmacological Society Shanghai Institute of Materia Medica Chinese Academy of Sciences http://www.chinaphar.com Metabolism and metabolic inhibition of cilnidipine
More informationCYTOCHROME P-450 3A4 AND 2C8 ARE INVOLVED IN ZOPICLONE METABOLISM
0090-9556/99/2709-1068 1073$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 27, No. 9 Copyright 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. CYTOCHROME P-450
More informationKARTHIK VENKATAKRISHNAN, LISA L. VON MOLTKE, and DAVID J. GREENBLATT
0022-3565/01/2971-326 337$3.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 297, No. 1 Copyright 2001 by The American Society for Pharmacology and Experimental Therapeutics 3324/893791
More informationHigh-Throughput CYP Inhibition Screening with Drug Probe Substrates: The RapidFire Advantage
High-Throughput CYP Inhibition Screening with Drug Probe Substrates: The RapidFire Advantage David M. Stresser, Ph.D. Program Manager BD Gentest SM Contract Research Services November 11, 2009 Presentation
More informationCharacterization of human cytochrome P-450 enzymes involved in the metabolism of. the piperidine-type phenothiazine neuroleptic thioridazine
DMD Fast This Forward. article has not Published been copyedited on and November formatted. The 4, final 2005 version as doi:10.1124/dmd.105.006445 may differ from this version. DMD #6445 Characterization
More informationIn vitro metabolism of montelukast by Cytochrome P450s (CYPs) and UDPglucuronosyltransferases
In vitro metabolism of montelukast by Cytochrome P450s (CYPs) and UDPglucuronosyltransferases (UGTs) Josiane de Oliveira Cardoso, Regina Vincenzi Oliveira, Jessica Bo Li Lu Zeruesenay Desta Department
More informationHIROSHI YAMAZAKI, KIYOSHI INOUE, PETER M. SHAW, WILLIAM J. CHECOVICH, F. PETER GUENGERICH and TSUTOMU SHIMADA
0022-3565/97/2832-0434$03.00/0 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 283, No. 2 Copyright 1997 by The American Society for Pharmacology and Experimental Therapeutics Printed in
More informationIdentification of Human Cytochrome P450 Isozymes Involved in Diphenhydramine N-Demethylation
0090-9556/07/3501-72 78$20.00 DRUG METABOLISM AND DISPOSITION Vol. 35, No. 1 Copyright 2007 by The American Society for Pharmacology and Experimental Therapeutics 12088/3160040 DMD 35:72 78, 2007 Printed
More informationStereoselective Metabolism of Bufuralol Racemate and Enantiomers in Human Liver Microsomes
0022-3565/02/3031-172 178$7.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 303, No. 1 Copyright 2002 by The American Society for Pharmacology and Experimental Therapeutics 36533/1006673
More informationROLES OF HUMAN CYP2A6 AND 2B6 AND RAT CYP2C11 AND 2B1 IN THE 10-HYDROXYLATION OF ( )-VERBENONE BY LIVER MICROSOMES
0090-9556/03/3108-1049 1053$7.00 DRUG METABOLISM AND DISPOSITION Vol. 31, No. 8 Copyright 2003 by The American Society for Pharmacology and Experimental Therapeutics 1076/1078953 DMD 31:1049 1053, 2003
More informationEnantioselectivity in the cytochrome P450-dependent conversion of tegafur to 5-fluorouracil in human liver microsomes
Enantioselectivity in the cytochrome P450-dependent conversion of tegafur to 5-fluorouracil in human liver microsomes Ikuo Yamamiya 1,2, Kunihiro Yoshisue 1, Yuji Ishii 2, Hideyuki Yamada 2 & Ken-ichiro
More informationENHANCEMENT OF CYTOCHROME P-450 3A4 CATALYTIC ACTIVITIES BY CYTOCHROME b 5 IN BACTERIAL MEMBRANES
0090-9556/99/2709-0999 1004$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 27, No. 9 Copyright 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. ENHANCEMENT OF
More informationIN VITRO BIOTRANSFORMATION OF SILDENAFIL (VIAGRA): IDENTIFICATION OF HUMAN CYTOCHROMES AND POTENTIAL DRUG INTERACTIONS
0090-9556/00/2804-0392 397$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 28, No. 4 Copyright 2000 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. IN VITRO BIOTRANSFORMATION
More informationPilot experiments to investigate the glucuronidation of axitinib with human liver microsomes.
Zientek MA, Goosen TC, Tseng E, Lin J, Bauman JN, Walker GS, Kang P, Jiang Y, Freiwald S, Neul D and Smith BJ. In Vitro Kinetic Characterization of Axitinib Metabolism. Drug Metab Dispos. Supplemental
More informationmediating omeprazole metabolism
Br J clin Pharmac 1993; 36: 521-530 Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism TOMMY ANDERSSON1' 2, JOHN 0. MINERS2, MAURICE E. VERONESE2, WICHITTRA TASSANEEYAKUL2,
More informationTHE INTERACTIONS OF A SELECTIVE PROTEIN KINASE C BETA INHIBITOR WITH THE HUMAN CYTOCHROMES P450
0090-9556/02/3009-957 961$7.00 DRUG METABOLISM AND DISPOSITION Vol. 30, No. 9 Copyright 2002 by The American Society for Pharmacology and Experimental Therapeutics 709/1002395 DMD 30:957 961, 2002 Printed
More informationPathways of Carbamazepine Bioactivation in Vitro. III. The Role of Human Cytochrome P450 Enzymes in the Formation of 2,3-Dihydroxycarbamazepine S
Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2008/05/07/dmd.107.019562.dc1 0090-9556/08/3608-1637 1649$20.00 DRUG METABOLISM AND DISPOSITION Vol. 36,
More informationBIOSYNTHESIS OF ALL-TRANS-RETINOIC ACID FROM ALL-TRANS-RETINOL: CATALYSIS OF ALL-TRANS-RETINOL OXIDATION BY HUMAN P-450 CYTOCHROMES
0090-9556/00/2803-0315 322$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 28, No. 3 Copyright 2000 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. BIOSYNTHESIS OF
More informationDRUG INTERACTION BETWEEN SIMVASTATIN AND ITRACONAZOLE IN MALE AND FEMALE RATS
0090-9556/01/2907-1068 1072$3.00 DRUG METABOLISM AND DISPOSITION Vol. 29, No. 7 Copyright 2001 by The American Society for Pharmacology and Experimental Therapeutics 331/915884 DMD 29:1068 1072, 2001 Printed
More informationDAPSONE ACTIVATION OF CYP2C9-MEDIATED METABOLISM: EVIDENCE FOR ACTIVATION OF MULTIPLE SUBSTRATES AND A TWO-SITE MODEL
0090-9556/01/2907-1029 1034$3.00 DRUG METABOLISM AND DISPOSITION Vol. 29, No. 7 Copyright 2001 by The American Society for Pharmacology and Experimental Therapeutics 352/914007 DMD 29:1029 1034, 2001 Printed
More informationMetabolism and Metabolic Inhibition of Xanthotoxol in Human Liver Microsomes
Virginia Commonwealth University VCU Scholars Compass Medicinal Chemistry Publications Dept. of Medicinal Chemistry 216 Metabolism and Metabolic Inhibition of Xanthotoxol in Human Liver Microsomes Zhongnv
More informationMECHANISM-BASED INACTIVATION OF CYP2C11 BY DICLOFENAC
0090-9556/01/2909-1190 1195$3.00 DRUG METABOLISM AND DISPOSITION Vol. 29, No. 9 Copyright 2001 by The American Society for Pharmacology and Experimental Therapeutics 400/923028 DMD 29:1190 1195, 2001 Printed
More informationCYTOCHROME P450: Structure-Function
MEDCH 527 AE Jan. 4-6, 2017 CYTCHME P450: Structure-Function 1. General P450 Characteristics and Taxonomy 2. Human P450s Substrate and Inhibitor Selectivities 3. Structure-Function Aspects of Ligand Binding,
More informationThe metabolism of 1 - and 4-hydroxymidazolam by glucuronide conjugation is. largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7
DMD Fast This article Forward. has not Published been copyedited on and August formatted. 16, The 2010 final version as doi:10.1124/dmd.110.035295 may differ from this version. The metabolism of 1 - and
More informationMetabolism of the active metabolite of quetiapine, N-desalkylquetiapine, in
DMD Fast This article Forward. has not been Published copyedited on and June formatted. 11, The 2012 final version as doi:10.1124/dmd.112.045237 may differ from this version. Metabolism of the active metabolite
More informationINVOLVEMENT OF CYTOCHROMES P-450 2E1 AND 3A4 IN THE 5-HYDROXYLATION OF SALICYLATE IN HUMANS
0090-9556/99/2703-0322 326$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 27, No. 3 Copyright 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. INVOLVEMENT OF
More informationTHE ALKALOID RUTAECARPINE IS A SELECTIVE INHIBITOR OF CYTOCHROME P450 1A IN MOUSE AND HUMAN LIVER MICROSOMES
0090-9556/02/3003-349 353$3.00 DRUG METABOLISM AND DISPOSITION Vol. 30, No. 3 Copyright 2002 by The American Society for Pharmacology and Experimental Therapeutics 513/966050 DMD 30:349 353, 2002 Printed
More informationCONTRIBUTION OF CYP3A4, CYP2B6, AND CYP2C9 ISOFORMS TO N-DEMETHYLATION OF KETAMINE IN HUMAN LIVER MICROSOMES
0090-9556/02/3007-853 858$7.00 DRUG METABOLISM AND DISPOSITION Vol. 30, No. 7 Copyright 2002 by The American Society for Pharmacology and Experimental Therapeutics 654/992225 DMD 30:853 858, 2002 Printed
More informationMetabolism of 1 - and 4-Hydroxymidazolam by Glucuronide Conjugation Is Largely Mediated by UDP-Glucuronosyltransferases 1A4, 2B4, and 2B7
0090-9556/10/3811-2007 2013$20.00 DRUG METABOLISM AND DISPOSITION Vol. 38, No. 11 Copyright 2010 by The American Society for Pharmacology and Experimental Therapeutics 35295/3635725 DMD 38:2007 2013, 2010
More informationPrilocaine- and Lidocaine-induced Methemoglobinemia is Caused by Human. Carboxylesterase-, CYP2E1- and CYP3A4-mediated Metabolic Activation
DMD Fast This article Forward. has not been Published copyedited on and March formatted. 25, The 2013 final version as doi:10.1124/dmd.113.051714 may differ from this version. Prilocaine- and Lidocaine-induced
More informationPREDICTION OF IN VIVO DRUG-DRUG INTERACTIONS BETWEEN TOLBUTAMIDE AND VARIOUS SULFONAMIDES IN HUMANS BASED ON IN VITRO EXPERIMENTS
0090-9556/00/2804-0475 481$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 28, No. 4 Copyright 2000 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. PREDICTION OF IN
More informationSTEREOSELECTIVE METABOLISM OF LANSOPRAZOLE BY HUMAN LIVER CYTOCHROME P450 ENZYMES
0090-9556/03/3110-1227 1234$7.00 DRUG METABOLISM AND DISPOSITION Vol. 31, No. 10 Copyright 2003 by The American Society for Pharmacology and Experimental Therapeutics 1086/1095069 DMD 31:1227 1234, 2003
More informationHuman cytochrome P450 mono-oxygenase system is suppressed by propofol
British Journal of Anaesthesia 1995; 74: 558-562 Human cytochrome P450 mono-oxygenase system is suppressed by propofol T. L. CHEN, T. H. UENG, S. H. CHEN, P. H. LEE, S. Z. FAN AND C. C. LIU Summary We
More informationCaveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters
Caveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters Uwe Fuhr, University Hospital Cologne 1 How to Safeguard that Metrics Reflect E/T Activity? in healthy
More informationSorafenib (free base, >99%) was obtained from Chemie Tek (Indianapolis, IN), and
Supplemental Methods Chemicals and Reagents Sorafenib (free base, >99%) was obtained from Chemie Tek (Indianapolis, IN), and isotopically-labeled 13 C- 2 H 3 -sorafenib (labeled atoms on N-methyl position)
More informationRat cytochrome P450 2C11 in liver microsomes involved in oxidation of. anesthetic agent propofol and deactivated by prior treatment with
DMD Fast This article Forward. has not been Published copyedited on and August formatted. 8, The 2006 final version as doi:10.1124/dmd.106.011627 may differ from this version. Rat cytochrome P450 2C11
More informationFORMATION OF A DIHYDROXY METABOLITE OF PHENYTOIN IN HUMAN LIVER MICROSOMES/CYTOSOL: ROLES OF CYTOCHROMES P450 2C9, 2C19, AND 3A4
0090-9556/00/2811-1361 1368$03.00/0 DRUG METABOLISM AND DISPOSITION Vol. 28, No. 11 Copyright 2000 by The American Society for Pharmacology and Experimental Therapeutics 63/859475 DMD 28:1361 1368, 2000
More informationCATALYTIC SPECIFICITY OF CYP2D ISOFORMS IN RAT AND HUMAN
0090-9556/02/3009-970 976$7.00 DRUG METABOLISM AND DISPOSITION Vol. 30, No. 9 Copyright 2002 by The American Society for Pharmacology and Experimental Therapeutics 696/1004051 DMD 30:970 976, 2002 Printed
More informationIdentification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism
Br J clin Pharmac 1994; 37: 597-604 dentification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism TOMMY ANDERSSON" 2, JOHN 0. MNERS', MAURCE E. VERONESE' & DONALD J. BRKETT'
More informationStereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion, and 49-OH-bupropion in vitro
1521-009X/44/10/1709 1719$25.00 http://dx.doi.org/10.1124/dmd.116.072363 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 44:1709 1719, October 2016 Copyright ª 2016 by The Author(s) This is an open access
More informationCharacterisation of the cytochrome P450 enzymes involved
Br J clin Pharmac 1994; 38: 557-566 Characterisation of the cytochrome P45 enzymes involved in the in vitro metabolism of granisetron J. C. BLOOMER1, S. J. BALDWIN1, G. J. SMITH', A. D. AYRTON2, S. E.
More informationCHARACTERIZATION OF THE IN VITRO BIOTRANSFORMATION OF THE HIV-1 REVERSE TRANSCRIPTASE INHIBITOR NEVIRAPINE BY HUMAN HEPATIC CYTOCHROMES P-450
0090-9556/99/2712-1488 1495$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 27, No. 12 Copyright 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. CHARACTERIZATION
More informationAn Evaluation of the Dilution Method for Identifying Metabolism-Dependent Inhibitors of Cytochrome P450 Enzymes
9-9556/11/398-137 1387$25. DRUG METABOLISM AND DISPOSITION Vol. 39, No. 8 Copyright 211 by The American Society for Pharmacology and Experimental Therapeutics 38596/3724 DMD 39:137 1387, 211 Printed in
More informationBIOCHEMISTRY and MOLECULAR BIOLOGY INTERNATIONAL DIFFERENTIAL INHIBITION OF AFLATOXIN B1 OXIDATION BY GESTODENE ACTION ON HUMAN LIVER MICROSOMES
Vol. 43, No. 4, November 1997 Pages 839-846 DIFFERENTIAL INHIBITION OF AFLATOXIN B1 OXIDATION BY GESTODENE ACTION ON HUMAN LIVER MICROSOMES Bok Ryang Kim,* Hyun Sook Oh,** and Dong-Hyun Kim ~t'l *Department
More informationCytochrome P450 2E1 is the Principal Catalyst of Human Oxidative Halothane Metabolism in Vitro 1
0022-3565/97/2811-0400$03.00/0 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 281, No. 1 Copyright 1997 by The American Society for Pharmacology and Experimental Therapeutics Printed in
More informationANTHONY J. LEE, JOSEPH W. KOSH, ALLAN H. CONNEY, 1 and BAO TING ZHU. ABSTRACT We characterized the NADPH-dependent metabolism of 17 estradiol
0022-3565/01/2982-420 432$3.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 298, No. 2 Copyright 2001 by The American Society for Pharmacology and Experimental Therapeutics 3751/916932
More informationInhibitory Effect of Antituberculosis Drugs on Human Cytochrome P450-Mediated Activities
J Pharmacol Sci 96, 293 300 (2004) Journal of Pharmacological Sciences 2004 The Japanese Pharmacological Society Full Paper Inhibitory Effect of Antituberculosis Drugs on Human Cytochrome P450-Mediated
More informationCytochrome P450 enzymes are involved in the metabolism of foreign substances
KHAN, MOHAMMAD MAZAMAL, M.S. Inhibition of Cytochrome P450 2E1 and Cytochrome P450 2A6 by Essential Oils: Tarragon (Artemisia dracunculus) and Basil (Ocimum basilicum). (2014) Directed by Dr. Gregory M.
More informationRole of Human Liver Microsomal CYP3A4 and CYP2B6 in Catalyzing N-Dechloroethylation of Cyclophosphamide and Ifosfamide
Biochemical Pharmacology, Vol. 59, pp. 961 972, 2000. ISSN 0006-2952/00/$ see front matter 2000 Elsevier Science Inc. All rights reserved. PII S0006-2952(99)00410-4 Role of Human Liver Microsomal CYP3A4
More informationMetabolism of Endosulfan- by Human Liver Microsomes and Its Utility as a Simultaneous in Vitro Probe for CYP2B6 and CYP3A4
0090-9556/06/3410-1779 1785$20.00 DRUG METABOLISM AND DISPOSITION Vol. 34, No. 10 Copyright 2006 by The American Society for Pharmacology and Experimental Therapeutics 10199/3142092 DMD 34:1779 1785, 2006
More informationTHE GASTROPROKINETIC AND ANTIEMETIC DRUG METOCLOPRAMIDE IS A SUBSTRATE AND INHIBITOR OF CYTOCHROME P450 2D6
0090-9556/02/3003-336 343$3.00 DRUG METABOLISM AND DISPOSITION Vol. 30, No. 3 Copyright 2002 by The American Society for Pharmacology and Experimental Therapeutics 500/964304 DMD 30:336 343, 2002 Printed
More informationIdenti cation of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine
Identi cation of the human cytochrome P45 isoforms mediating in vitro -dealkylation of perphenazine Ole V. Olesen & Kristian Linnet Institute for Basic Psychiatric Research, Department of Biological Psychiatry,
More informationMetabolic differences in colon mucosal cells
Metabolic differences in colon mucosal cells Ross A. McKinnon a Wendy M. Burgess a, Frank J. Gonzalez b and Michael E. McManus c a Department of Clinical Pharmacology, Flinders University, South Australia
More informationCulture Hepatocytes in Human Plasma to Count the free Concentration of Drug in Evaluation of Drug-drug Interaction. Chuang Lu
Culture Hepatocytes in Human Plasma to Count the free Concentration of Drug in Evaluation of Drug-drug nteraction Chuang Lu Millennium, The Takeda Oncology Company Cambridge, MA, USA DD 205, Seattle, 6/29/205
More informationDiltiazem Inhibition of Cytochrome P-450 3A Activity Is Due To Metabolite Intermediate Complex Formation 1
0022-3565/99/2903-1116$03.00/0 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 290, No. 3 Copyright 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in
More informationCytochrome P450 Drug Interaction Table Flockhart Table
Cytochrome P450 Drug Interaction Table Flockhart Table The table contains lists of drugs in columns under the designation of specific cytochrome P450 isoforms. CYTOCHROME P450 DRUG INTERACTION TABLE A
More informationMechanism-Based Inhibition of CYP3A4 by Constituents of Zingiber aromaticum
March 2005 Biol. Pharm. Bull. 28(3) 495 499 (2005) 495 Mechanism-Based Inhibition of CYP3A4 by Constituents of Zingiber aromaticum Tepy USIA, a Tadashi WATABE, a Shigetoshi KADOTA, a and Yasuhiro TEZUKA*,a,b
More informationMIE KASAHARA, HISASHI SUZUKI, AND IZUMI KOMIYA. Pharmacokinetics Department, Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd.
0090-9556/00/2804-0409 417$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 28, No. 4 Copyright 2000 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. STUDIES ON THE
More informationA HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC ASSAY FOR LERCANIDIPINE HYDROCHLORIDE
Int. J. Chem. Sci.: 6(1), 2008, 441-446 A HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC ASSAY FOR LERCANIDIPINE HYDROCHLORIDE S. APPALA RAJU, ARVIND B. KARADI and SHOBHA MANJUNATH HKES s College of Pharmacy,
More informationInteractions between CYP2C9 and CYP2C19 in Reconstituted Binary. Systems Influence their Catalytic Activity: Possible rationale for the inability
DMD Fast This Forward. article has not Published been copyedited on and October formatted. 14, The 2004 final version as doi:10.1124/dmd.104.001578 may differ from this version. DMD #1578R Interactions
More informationBritish Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2006.02627.x An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors,
More informationREVERSE PHASE HPLC METHOD FOR THE ANALYSIS OF ALFUZOSIN HYDROCHLORIDE IN PHARMACEUTICAL DOSAGE FORMS
Int. J. Chem. Sci.: 6(1), 2008, 399-404 REVERSE PHASE HPLC METHOD FOR THE ANALYSIS OF ALFUZOSIN HYDROCHLORIDE IN PHARMACEUTICAL DOSAGE FORMS S. APPALA RAJU, ARVIND B. KARADI and SHOBHA MANJUNATH HKES s
More informationP450I I E 1 Gene : Dra I. Human Cytochrome Polymorphism and
Tohoku J. Exp. Med., 1992, 168, 113-117 Human Cytochrome Polymorphism and P450I I E 1 Gene : Dra I Susceptibility to Cancer FUMIYUKI VEMATSUHIDEAKI KIKUCHI*, MASAKICHI MOTOMIYA j', TATSUYA ABE j', CHIKASHI
More informationMEDCH/PCEUT 527 ADVANCED DRUG METABOLISM 2019 Course Coordinators: Allan Rettie and Ken Thummel When/ Where:
MEDCH/PCEUT 527 ADVACED DRUG METABLISM 2019 Course Coordinators: Allan Rettie and Ken Thummel When/ Where: 2.30 4.00 pm MWF in H074 Date Topic Instructor Jan 7 Introduction Rettie/Thummel Jan 9 P450 I:
More informationab CYP2C19 Activity Assay Kit (Fluorometric)
Version 2 Last updated 1 March 2017 ab211072 CYP2C19 Activity Assay Kit (Fluorometric) For the rapid, sensitive and accurate measurement of cytochrome P450 2C19 (CYP2C19) activity in various samples. This
More informationRole of CYP3A4 in Human Hepatic Diltiazem N-Demethylation: Inhibition of CYP3A4 Activity by Oxidized Diltiazem Metabolites 1
0022-3565/97/2821-0294$03.00/0 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 282, No. 1 Copyright 1997 by The American Society for Pharmacology and Experimental Therapeutics Printed in
More informationTheophylline has no advantages over caffeine as a putative model drug for assessing CYP1A2 activity in humans
Br J Clin Pharmacol 1997; 43: 253 258 Theophylline has no advantages over caffeine as a putative model drug for assessing CYP1A2 activity in humans Birgitte Buur Rasmussen & Kim Brøsen Department of Clinical
More informationScreening of Antihistamine Agents (Diphenhydramine) with Blood and Urine Samples by REMEDi-HS System
Screening of Antihistamine Agents (Diphenhydramine) with Blood and Urine Samples by REMEDi-HS System Ohtsuji M, Ohshima T, Takayasu T, Nishigami J, Kondo T, Lin Z, Minamino T Department of Legal Medicine,
More informationIDENTIFICATION OF HUMAN LIVER CYTOCHROME P450 ENZYMES RESPONSIBLE FOR THE METABOLISM OF LONAFARNIB (SARASAR)
0090-9556/06/3404-628 635$20.00 DRUG METABOLISM AND DISPOSITION Vol. 34, No. 4 Copyright 2006 by The American Society for Pharmacology and Experimental Therapeutics 7906/3102946 DMD 34:628 635, 2006 Printed
More informationtheobromine b Chocolate Theobromine cacao Theobromine b Adenosine Adenosine receptor Opium Papaver somniferum Codeine a, Endorphins Opioid receptor
Table 1 Relationships between plant neurotoxins commonly used as drugs and CNS receptors. Drug Plant Toxin Neurotransmitter Receptor Tobacco, Pituri Nicotiana, Duboisia Nicotine a Acetylcholine Nicotinic
More informationCYTOCHROME P450 2C8 AND FLAVIN-CONTAINING MONOOXYGENASES ARE INVOLVED IN THE METABOLISM OF TAZAROTENIC ACID IN HUMANS
0090-9556/03/3104-476 481$7.00 DRUG METABOLISM AND DISPOSITION Vol. 31, No. 4 Copyright 2003 by The American Society for Pharmacology and Experimental Therapeutics 895/1052414 DMD 31:476 481, 2003 Printed
More informationCytochrome P450 2B6 (CYP2B6) Catalyzes the Formation of Pharmacologically Active Sibutramine Metabolites in Human Liver Microsomes
This article has not been copyedited and formatted. The final version may differ from this version. ktkjyw^y^ DMD Fast Forward. Published on May 12, 2008 as doi:10.1124/dmd.108.020727 Cytochrome P450 2B6
More informationSupplemental material to this article can be found at:
Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2015/07/28/dmd.115.064949.dc1 1521-009X/43/10/1632 1641$25.00 http://dx.doi.org/10.1124/dmd.115.064949
More informationAn Evaluation of the CYP450 Inhibition Potential of Lisdexamfetamine in. Human Liver Microsomes
DMD Fast This Forward. article has not Published been copyedited on and October formatted. 11, The 2006 final version as doi:10.1124/dmd.106.011973 may differ from this version. TITLE PAGE An Evaluation
More informationFUNCTIONAL CHARACTERIZATION OF CYTOCHROME P450 2B6 ALLELIC VARIANTS
0090-9556/03/3104-398 403$7.00 DRUG METABOLISM AND DISPOSITION Vol. 31, No. 4 Copyright 2003 by The American Society for Pharmacology and Experimental Therapeutics 973/1050100 DMD 31:398 403, 2003 Printed
More informationIt the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues.
It the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues. Primarily depends on: 1.Regional blood flow. 2.Capillary permeability. 3.Protein
More informationInfluence of fluvoxamine on carvedilol metabolism and plasma disposition in vitro and in vivo experiments
Influence of fluvoxamine on carvedilol metabolism and plasma disposition in vitro and in vivo experiments MARIA BIANCA ABRUDAN* 1, DANA MARIA MUNTEAN 1, DANIELA SAVETA POPA 2, LAURIAN VLASE 1, ANA-MARIA
More informationDevelopment, Estimation and Validation of Lisinopril in Bulk and its Pharmaceutical Formulation by HPLC Method
ISSN: 0973-4945; CODEN ECJAO E- Chemistry http://www.e-journals.net 2012, 9(1), 340-344 Development, Estimation and Validation of Lisinopril in Bulk and its Pharmaceutical Formulation by PLC Method V.
More informationINTERACTION OF CISAPRIDE WITH THE HUMAN CYTOCHROME P450 SYSTEM: METABOLISM AND INHIBITION STUDIES
0090-9556/00/2807-0789 800$03.00/0 DRUG METABOLISM AND DISPOSITION Vol. 28, No. 7 Copyright 2000 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. DMD 28:789 800,
More informationEnhanced method development workflow for modern LC and SFC
Enhanced method development workflow for modern LC and SFC Davy GUILLARME 18 th of September 2014 What can be done with modern LC? MONOLITHS HIGH TEMPERATURE 1 000 000 plates 12 m column 120 C.60 0.40
More informationISSN: ; CODEN ECJHAO E-Journal of Chemistry 2011, 8(3),
ISSN: 0973-4945; CODEN ECJHAO E- Chemistry http://www.e-journals.net 2011, 8(3), 1275-1279 Simultaneous Determination of Paracetamol, Phenylephrine Hydrochloride, Oxolamine Citrate and Chlorpheniramine
More informationDiscovery of a highly selective CYP3A4 inhibitor suitable for reaction. phenotyping studies and differentiation of CYP3A4 and CYP3A5
DMD Fast This article Forward. has not been Published copyedited on and June formatted. 13, The 2012 final version as doi:10.1124/dmd.112.046144 may differ from this version. Discovery of a highly selective
More informationRole of CYP2E1 in deramciclane metabolism. Chemical Research Center, Hungarian Academy of Sciences (K.M., K.K., E.H., L.V.)
DMD This Fast article Forward. has not been Published copyedited and on formatted. June 2, The 2005 final as version doi:10.1124/dmd.105.003772 may differ from this version. 1 Role of CYP2E1 in deramciclane
More informationResearch Article Selective Inhibition of Bakuchicin Isolated from Psoralea corylifolia on CYP1A in Human Liver Microsomes
Evidence-Based Complementary and Alternative Medicine Volume 216, Article ID 5198743, 7 pages http://dx.doi.org/1.1155/216/5198743 Research Article Selective Inhibition of Bakuchicin Isolated from Psoralea
More informationA New Stability-Indicating and Validated RP-HPLC Method for the Estimation of Liraglutide in Bulk and Pharmaceutical Dosage Forms
OPEN ACCESS Eurasian Journal of Analytical Chemistry ISSN: 1306-3057 2017 12(2):31-44 DOI 10.12973/ejac.2017.00152a A New Stability-Indicating and Validated RP-HPLC Method for the Estimation of Liraglutide
More information